Press release
Pulmonary Arterial Hypertension pipeline is witnessing global growth, with over 55 therapies currently under development, according to DelveInsight's market intelligence report.
Pulmonary Arterial Hypertension pipeline
According to DelveInsight's analysis, the global PAH pipeline consists of more than 55 key companies working on over 55 therapeutic candidates. The report provides a thorough assessment of clinical trials, treatment strategies, mechanisms of action, administration routes, and recent advancements influencing the PAH treatment ecosystem.
The report titled "Pulmonary Arterial Hypertension Pipeline Insight, 2026" by DelveInsight offers a comprehensive overview of the current clinical landscape along with future opportunities expected to drive growth in the PAH market.
This pipeline analysis presents an extensive evaluation of both clinical and commercial aspects of drug candidates, covering stages from early discovery to marketed therapies. It also includes detailed drug profiles outlining mechanisms of action, clinical progress, regulatory milestones such as NDA approvals (if applicable), and key developments including partnerships, mergers and acquisitions, funding activities, technological innovations, and regulatory updates.
Request for free sample report @ Pulmonary Arterial Hypertension Pipeline Insight [https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Key Highlights from the Pulmonary Arterial Hypertension Pipeline Report:
* Companies across the globe are continuously investing in innovative therapies for PAH, with significant advancements achieved in recent years.
* Major pharmaceutical and biotechnology players such as Aerovate Therapeutics, Novartis, Keros Therapeutics, Vigonvita Life Sciences, Insmed Incorporated, Chugai Pharmaceutical, Merck Sharp & Dohme, Janssen Pharmaceutical, Actelion, Gossamer Bio, Lung Biotechnology PBC, United Therapeutics, Gilead Sciences, Acceleron Pharma, Eiger BioPharmaceuticals, and AstraZeneca are focused on developing next-generation PAH treatments.
* A number of promising pipeline therapies are advancing through different stages of clinical trials, including AV-101, LTP001, KER-012, TPN171H, Treprostinil Palmitil, Satralizumab, Sotatercept, Macitentan, ACT-293987, GB002 (seralutinib), Parenteral Treprostinil, Ralinepag, Selonsertib, ubenimex, Olaparib, among others, which are anticipated to reshape the future PAH treatment landscape.
* In December 2025, tiakis Biotech AG announced the successful completion of a comprehensive data package supporting the advancement of Tiprelestat into Phase II clinical trials for PAH. This follows positive preclinical GLP-tox results. Tiprelestat is a novel neutrophil elastase inhibitor and BMPR2 enhancer designed to reduce inflammation and reverse vascular remodeling in PAH patients.
* In November 2025, Inhibikase Therapeutics, Inc. (Nasdaq: IKT) disclosed its plans to initiate a global Phase III trial for IKT-001 under the IMPROVE-PAH study, expected to begin in early 2026.
* Also in November 2025, Cereno Scientific applied for FDA approval to begin a global clinical study evaluating its oral drug candidate CS1, originally developed for seizure disorders, in PAH patients. If approved, the Phase IIb placebo-controlled study is projected to commence in the first half of 2026 in partnership with a global CRO.
* In September 2025, AllRock Bio Inc. raised $50 million in Series A funding, co-led by Versant Ventures and Westlake BioPartners, to support the advancement of ROC-101, an oral pan-ROCK inhibitor licensed from Sanofi, into Phase II trials for PAH and ILD-PH.
* In August 2025, VASTHERA Co., Ltd. received FDA IND approval to initiate a Phase I clinical trial for VTB-10, a first-in-class Chemzyme designed to mimic peroxiredoxin activity and target oxidative stress in PAH.
* In March 2025, Merck (NYSE: MRK), known as MSD outside North America, announced results from the Phase III ZENITH trial of WINREVAIR Trademark (sotatercept-csrk), demonstrating a 76% reduction in the risk of major morbidity and mortality compared to placebo in high-risk PAH patients.
* Earlier, in January 2025, Merck released preliminary findings from the same ZENITH study, highlighting strong clinical benefits of WINREVAIR in patients classified under WHO functional class III/IV.
* In October 2024, Inhibikase Therapeutics, Inc. secured $110 million through a private placement to fund its Phase IIb '702' clinical trial and support additional corporate initiatives.
Pulmonary Arterial Hypertension Overview
Pulmonary Arterial Hypertension is a rare and progressive condition marked by elevated blood pressure in the pulmonary arteries. This increased pressure puts significant strain on the right side of the heart, leading to symptoms such as shortness of breath, fatigue, chest pain, and swelling in the extremities. PAH can develop due to unknown causes, genetic predisposition, or as a result of other conditions such as connective tissue disorders or congenital heart defects. Although there is no definitive cure, existing treatment approaches-including medications, oxygen therapy, and lifestyle changes-help manage symptoms and improve quality of life.
Get a Free Sample PDF Report to know more about Pulmonary Arterial Hypertension Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-pipeline-insight [https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Emerging Drugs in the Pulmonary Arterial Hypertension Pipeline
Several innovative therapies are currently being investigated across various clinical stages, including:
* TYVASO / TYVASO DPI / TREPROST (treprostinil) - United Therapeutics / Mochida Pharmaceutical
* OPSYNVI / YUVANCI (macitentan + tadalafil) - Johnson & Johnson
* WINREVAIR (sotatercept) - Merck
* UPTRAVI (selexipag) - Johnson & Johnson / Nippon Shinyaku
* AV-101 - Aerovate Therapeutics
* LTP001 - Novartis
* KER-012 - Keros Therapeutics
* TPN171H - Vigonvita Life Sciences
* Treprostinil Palmitil - Insmed Incorporated
* Satralizumab - Chugai Pharmaceutical
* Sotatercept - Merck Sharp & Dohme
* Macitentan - Janssen Pharmaceutical
* ACT-293987 - Actelion
* GB002 (seralutinib) - Gossamer Bio
* Parenteral Treprostinil - Lung Biotechnology PBC
* Ralinepag - United Therapeutics
* Selonsertib - Gilead Sciences
* Sotatercept - Acceleron Pharma
* ubenimex - Eiger BioPharmaceuticals
* Olaparib - AstraZeneca
Get a Free Sample PDF Report to know more about Pulmonary Arterial Hypertension Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-pipeline-insight [https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Pulmonary Arterial Hypertension Route of Administration and Molecule Classification
The Pulmonary Arterial Hypertension pipeline includes therapies delivered through various routes such as oral, parenteral, intravitreal, subretinal, and topical methods.
These therapies are also categorized based on molecular types, including monoclonal antibodies, peptides, polymers, small molecules, and gene-based treatments.
Pulmonary Arterial Hypertension Pipeline Segmentation
The report categorizes more than 55 pipeline candidates across different development stages:
* Phase III (advanced stage)
* Phase II (mid-stage)
* Phase I (early-stage)
* Preclinical and discovery phases
* Discontinued or inactive programs
Pulmonary Arterial Hypertension Market Drivers
* Rising global incidence of PAH
* A robust and expanding pipeline of therapies
* Development of innovative drug combinations
Pulmonary Arterial Hypertension Market Challenges
* High cost of treatment
* Low awareness in emerging markets
* Issues related to access and reimbursement
Request for Sample PDF Report for Pulmonary Arterial Hypertension Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Scope of the Pulmonary Arterial Hypertension Market Report
* Global: coverage
* Key Pulmonary Arterial Hypertension companies include Aerovate Therapeutics, Novartis, Keros Therapeutics, Vigonvita Life Sciences, Insmed Incorporated, Chugai Pharmaceutical, Merck Sharp & Dohme, Janssen Pharmaceutical, Actelion, Gossamer Bio, Lung Biotechnology PBC, United Therapeutics, Gilead Sciences, Acceleron Pharma, Eiger BioPharmaceuticals, AstraZeneca, and others
* Key Pulmonary Arterial Hypertension therapies include AV-101, LTP001, KER-012, TPN171H, Treprostinil Palmitil, Satralizumab, Sotatercept, Macitentan, ACT-293987, GB002 (seralutinib), Parenteral Treprostinil, Ralinepag, Selonsertib, ubenimex, Olaparib, among others
* Covers both marketed and emerging therapies
* Includes detailed analysis of market drivers and barriers
Request for Sample PDF Report for Pulmonary Arterial Hypertension Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Table of Contents
* Introduction to the PAH Report
* Executive Overview
* Disease Overview
* Analytical and Commercial Assessment
* Pipeline Therapeutics Overview
* Late-Stage Pipeline Products
* Mid-Stage Pipeline Products
* Early-Stage Pipeline Products
* Preclinical Candidates
* Therapeutic Evaluation
* Inactive or Discontinued Products
* Collaboration and Licensing Analysis
* Key Companies
* Key Therapies
* Unmet Needs
* Market Drivers and Challenges
* Future Outlook and Conclusions
* Analyst Insights
* Appendix
* About DelveInsight
About DelveInsight
DelveInsight is a prominent business consulting and market research firm specializing in the life sciences sector. The company assists pharmaceutical organizations by delivering comprehensive solutions aimed at enhancing performance. Additionally, it provides healthcare consulting services that support market analysis, enabling businesses to accelerate growth and effectively address industry challenges.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=pulmonary-arterial-hypertension-pipeline-is-witnessing-global-growth-with-over-55-therapies-currently-under-development-according-to-delveinsights-market-intelligence-report]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pulmonary Arterial Hypertension pipeline is witnessing global growth, with over 55 therapies currently under development, according to DelveInsight's market intelligence report. here
News-ID: 4471256 • Views: …
More Releases from ABNewswire
Balloon Valvuloplasty Device Market is projected to expand at a CAGR of 5.13% th …
Balloon valvuloplasty device manufacturers consist of BD, PFM Medical AG, NuMED, Balton, TORAY INDUSTRIES, INC., Translumina, InterValve Medical, Inc., OSYPKA AG, SURETECH MEDICAL INC., simeks, among others.
The Global Balloon Valvuloplasty Device Market is expected to experience consistent growth, with a projected CAGR of 5.13% over the forecast period from 2025 to 2032. The increasing incidence of cardiovascular diseases (CVDs), growing preference for minimally invasive cardiac treatments, ongoing innovations in interventional…
Factory Farming's Hidden Horrors: A Moral Reckoning for Farm Animals in 2026
Over 83 billion land animals yearly suffer deprivation: chickens crammed in battery cages tinier than A4 paper, denied wingspread or dust baths; sows in gestation crates unable to turn, atrophying in despair; dairy calves torn from mothers post-birth, isolated and bleating as their milk profits humans. Violating the Five Freedoms-from hunger, discomfort, pain, fear, distress-farms become suffering factories, urging collective action via HUF's insights.
As global awareness grows, the Humane Foundation…
Can AI Really Create Music Stars in Minutes
Music is not what it used to be. It seems the biggest shift occurs over time. In the 80s, 90s, and early 2000s, music producers and artists spent years of practice and thousands of dollars on studio time and other resources to get their singles and albums produced.
Today, you can create music with AI, edit, and publish songs using automated songwriting software and digital music production platforms in just a…
Gulali Gasimov emphasizes the importance of digital safety awareness and respons …
Image: https://www.abnewswire.com/upload/2026/04/15ee63cb950d081d840520980e4053a1.jpg
Children and Adolescents Do Not Put Their Phones Down - this is observable to all. According to experts, the problem does not lie with the device itself; rather, the issue is that children navigate the internet as if they were adults, yet they fail to recognize risks with adult-level awareness. According to Gulali Gasimov [https://share.google/ZQ1wGh6xmLVBP3wuk], digital safety begins not with intimidating the child, but with instilling appropriate behavioral habits.
The…
More Releases for Pulmonary
Innovation In Pulmonary Drug Delivery Devices Industry Trends Gaining Momentum i …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Pulmonary Drug Delivery Devices Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for pulmonary drug delivery devices has experienced significant growth in the past few years. The market is projected to increase from $49.52 billion in 2024 to $52.8 billion in 2025,…
Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers…
Global Pulmonary Arterial Hypertension Market Size
According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 5.2% from 2022 to 2027.
Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion.
Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC…
New Study: Pulmonary Drugs Market Report
The pulmonary drugs market is expected to witness unprecedented growth in the near future, thanks to large number of approvals from the FDA. The FDA approved a large number of pulmonary drugs for major illnesses like small-cell lung cancer, tuberculosis, and pneumonia over the past few years. Additionally, newly approved drugs also treat newly found diseases like obstructive sleep apnea. These approvals are in line with the recent trend of…
Pulmonary Drugs Market Forecast till 2025
Pulmonary Drugs Market – Boon for Diseased Lungs
Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated…
Pulmonary Drug Delivery Devices Market: Demand for Pulmonary Drug Delivery Devic …
This report on pulmonary drug delivery devices studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pulmonary/respiratory drugs and/or drug-device combinations as well as new entrants planning to enter this market.
This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments…
